Výsledky vyhledávání - "Lori McDermott"

Tumor antigen expression and survival of patients with previously treated advanced non-small cell lung cancer (NSCLC) receiving viagenpumatucel-L (HS-110) plus nivolumab

Autor: Daniel Morgensztern, Brian D. Piening, David H Taylor, Fred L. Robinson, Lyudmila Bazhenova, Saiama N. Waqar, Wael A. Harb, Lori McDermott, Jeff Hutchins, Roger B. Cohen, Nathan A. Pennell, Alexa K Dowdell

Publikováno v: Journal of Clinical Oncology. 38:9546-9546

9546 Background: Viagenpumatucel-L (HS-110) is an allogeneic cellular vaccine derived from a human lung adenocarcinoma cell line transfected with gp96-Ig fusion protein. Gp96-Ig functions as an antigen chaperone for dendritic cell activation and dire

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ac887b88d1a928de941e2c619ef94298
https://doi.org/10.1200/jco.2020.38.15_suppl.9546

Zobrazit plný text záznamu

Abstract B31: Viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)

Autor: Lori McDermott, Daniel Morgensztern, Wael A. Harb, Saiama N. Waqar, Jeff Hutchins, Roger B. Cohen, Nathan A. Pennell, Lyudmila Bazhenova

Publikováno v: Cancer Immunology Research. 8:B31-B31

Background: Viagenpumatucel-L (HS-110) is an allogeneic cellular vaccine derived from a human lung adenocarcinoma (Ad) cell line transfected with the gp96-Ig fusion protein that functions as an antigen chaperone for cross-presentation and dendritic c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6b1d1e0fc01a2c6d2b1cc9eefcd1d6ab
https://doi.org/10.1158/2326-6074.tumimm19-b31

Zobrazit plný text záznamu

Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC) after checkpoint inhibitor treatment failure

Autor: Lyudmila Bazhenova, Rachel E. Sanborn, Lori McDermott, Saiama N. Waqar, Jeff Hutchins, Corey J. Langer, David L. Rimm, Luis E. Raez, Roger B. Cohen, Daniel Morgensztern

Publikováno v: Journal of Clinical Oncology. 37:9109-9109

9109 Background: Viagenpumatucel-L (HS-110) is an allogeneic cellular vaccine derived from a human lung adenocarcinoma cell line transfected with the gp96-Ig fusion protein that functions as an antigen chaperone for cross presentation and dendritic c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b2f4ab40ef3b6f422c4840acbecce6ae
https://doi.org/10.1200/jco.2019.37.15_suppl.9109

Zobrazit plný text záznamu

Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC)

Autor: Daniel Morgensztern, Lyudmila Bazhenova, Lori McDermott, Roger B. Cohen, Saiama N. Waqar, Wael A. Harb, Jeff Hutchins, Vamsidhar Velcheti

Publikováno v: Journal of Clinical Oncology. 37:101-101

101 Background: Viagenpumatucel-L (HS-110) is an allogeneic cellular vaccine derived from a human lung adenocarcinoma (AD) cell line transfected with the gp96-Ig fusion protein. DURGA is a multi-cohort study evaluating the combination of HS-110 and i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d35bd167c3f33cd7987b32be4817941f
https://doi.org/10.1200/jco.2019.37.8_suppl.101

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání